Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
As of Nov 16, 2026, ANDA 212675 (Calcitonin-Salmon), held by Fresenius Kabi USA, was first approved by FDA on Dec 5, 2024, with 0 approved supplements and 0 published complete response letters.
First approved: Dec 5, 2024
Review: Standard
Supplements approved: 0
Complete response letters: 0
What It's For
From the FDA-approved label (Indications and Usage)
Calcitonin Salmon synthetic injection is a calcitonin, indicated for the following conditions:
Treatment of symptomatic Paget's disease of bone when alternative treatments are not suitable
Treatment of hypercalcemia
Treatment of postmenopausal osteoporosis when alternative treatments are not suitable. Fracture reduction efficacy has not been demonstrated Limitations of Use:
Due to the possible association between malignancy and calcitonin-salmon use, the need for continued therapy should be re-evaluated on a periodic basis ( 1.4, 5.3 ) 1.
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters